Viking Therapeutics, Inc. Common Stock Earnings Dividend
Earnings Summary
Revenue | $0Mn |
Net Profits | $-128.02Mn |
Net Profit Margins | -Inf% |
Viking Therapeutics, Inc. Common Stock’s revenue jumped NaN% since last year same period to $0Mn in the Q2 2026. On a quarterly growth basis, Viking Therapeutics, Inc. Common Stock has generated NaN% jump in its revenue since last 3-months.
Viking Therapeutics, Inc. Common Stock’s net profit fell -95.27% since last year same period to $-128.02Mn in the Q2 2026. On a quarterly growth basis, Viking Therapeutics, Inc. Common Stock has generated 19.14% jump in its net profits since last 3-months.
Viking Therapeutics, Inc. Common Stock’s net profit margin jumped NaN% since last year same period to -Inf% in the Q2 2026. On a quarterly growth basis, Viking Therapeutics, Inc. Common Stock has generated NaN% jump in its net profit margins since last 3-months.
Earnings per share (EPS) Estimates
EPS Estimate Current Quarter | 1 |
EPS Estimate Current Year | 1 |
Viking Therapeutics, Inc. Common Stock’s earning per share (EPS) estimates for the current quarter stand at 1 - a 182.64% jump from last quarter’s estimates.
Viking Therapeutics, Inc. Common Stock’s earning per share (EPS) estimates for the current year stand at 1.
Key Ratios
Earning Per Share (EPS) | -1.1 |
Viking Therapeutics, Inc. Common Stock’s earning per share (EPS) fell -89.66% since last year same period to -1.1 in the Q2 2026. This indicates that the Viking Therapeutics, Inc. Common Stock has generated -89.66% annual rate of fall in its earning per share (EPS) in the last 4 quarters.
Earnings Calendar
| Earnings Date | Estimated EPS | Reported EPS | Surprise % |
|---|---|---|---|
2026-04-30 | -0.91 | -1.37 | -50.55% |
2026-07-29 | -1.21 | -1.1 | 9.09% |
